KR20180004733A - 키나제 억제제로서의 헤테로시클릭 아미드 - Google Patents

키나제 억제제로서의 헤테로시클릭 아미드 Download PDF

Info

Publication number
KR20180004733A
KR20180004733A KR1020177033029A KR20177033029A KR20180004733A KR 20180004733 A KR20180004733 A KR 20180004733A KR 1020177033029 A KR1020177033029 A KR 1020177033029A KR 20177033029 A KR20177033029 A KR 20177033029A KR 20180004733 A KR20180004733 A KR 20180004733A
Authority
KR
South Korea
Prior art keywords
alkyl
optionally substituted
phenyl
membered heteroaryl
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020177033029A
Other languages
English (en)
Korean (ko)
Inventor
니얼 앤드류 앤더슨
디파크 반디오파디야이
알랭 클로드-마리 도강
프레데릭 쥐. 돈쉐
패트릭 엠. 에이담
니콜라스 에릭 파우셔
니콜라스 에스. 조지
필립 안토니 하리스
재 유. 정
브라이언 더블유. 킹
클라크 에이. 세혼
젬마 빅토리아 화이트
데이빗 더프 위스노스키
Original Assignee
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 filed Critical 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드
Publication of KR20180004733A publication Critical patent/KR20180004733A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
KR1020177033029A 2015-05-19 2016-05-19 키나제 억제제로서의 헤테로시클릭 아미드 Pending KR20180004733A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562163552P 2015-05-19 2015-05-19
US62/163,552 2015-05-19
US201562167359P 2015-05-28 2015-05-28
US62/167,359 2015-05-28
US201562197602P 2015-07-28 2015-07-28
US62/197,602 2015-07-28
PCT/IB2016/052948 WO2016185423A1 (en) 2015-05-19 2016-05-19 Heterocyclic amides as kinase inhibitors

Publications (1)

Publication Number Publication Date
KR20180004733A true KR20180004733A (ko) 2018-01-12

Family

ID=56080431

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177033029A Pending KR20180004733A (ko) 2015-05-19 2016-05-19 키나제 억제제로서의 헤테로시클릭 아미드

Country Status (35)

Country Link
US (4) US10590085B2 (https=)
EP (1) EP3298002B1 (https=)
JP (3) JP6700311B2 (https=)
KR (1) KR20180004733A (https=)
CN (2) CN112370452A (https=)
AU (2) AU2016263156B2 (https=)
CA (1) CA2986102C (https=)
CL (1) CL2017002908A1 (https=)
CO (1) CO2017011754A2 (https=)
CR (1) CR20170524A (https=)
CY (1) CY1124187T1 (https=)
DK (1) DK3298002T3 (https=)
DO (1) DOP2017000267A (https=)
EA (1) EA036452B1 (https=)
ES (1) ES2848398T3 (https=)
HR (1) HRP20210300T1 (https=)
HU (1) HUE053564T2 (https=)
IL (1) IL255246A0 (https=)
LT (1) LT3298002T (https=)
MA (1) MA42109B1 (https=)
MX (1) MX383935B (https=)
MY (1) MY192059A (https=)
NZ (1) NZ736665A (https=)
PE (1) PE20180508A1 (https=)
PH (1) PH12017502090A1 (https=)
PL (1) PL3298002T3 (https=)
PT (1) PT3298002T (https=)
RS (1) RS61568B1 (https=)
SG (1) SG11201708707UA (https=)
SI (1) SI3298002T1 (https=)
SM (1) SMT202100101T1 (https=)
TW (1) TWI730959B (https=)
UY (1) UY36680A (https=)
WO (1) WO2016185423A1 (https=)
ZA (1) ZA201707176B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2502911T (lt) 2004-06-24 2017-09-11 Vertex Pharmaceuticals Incorporated Atp surišančios kasetės transporterių moduliatoriai
EP1945632B1 (en) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
SI2225230T1 (sl) 2007-12-07 2017-03-31 Vertex Pharmaceuticals Incorporated Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
EP2639224B1 (en) 2007-12-07 2016-08-24 Vertex Pharmaceuticals Incorporated Process for producing cycloalkylcarboxiamido-pyridine benzoic acids
NZ720282A (en) 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
SI2408750T1 (sl) 2009-03-20 2015-11-30 Vertex Pharmaceuticals Incorporated Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
WO2013112804A1 (en) 2012-01-25 2013-08-01 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
EP2819670A1 (en) 2012-02-27 2015-01-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
JP6963896B2 (ja) 2013-11-12 2021-11-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
PT3221692T (pt) 2014-11-18 2021-09-10 Vertex Pharma Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência
EP3224245B1 (en) 2014-12-24 2018-09-12 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
TWI730959B (zh) 2015-05-19 2021-06-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
TW201831464A (zh) * 2016-11-18 2018-09-01 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
US20200062735A1 (en) 2017-02-27 2020-02-27 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
CA3063934A1 (en) 2017-05-17 2018-11-22 Denali Therapeutics Inc. Kinase inhibitors and uses thereof
AR113811A1 (es) 2017-10-31 2020-06-10 Hoffmann La Roche Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
WO2019224773A1 (en) * 2018-05-23 2019-11-28 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors
WO2019224774A1 (en) * 2018-05-23 2019-11-28 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors
WO2020044206A1 (en) 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors for use in the treatment cancer
CN113302193A (zh) 2019-01-11 2021-08-24 豪夫迈·罗氏有限公司 双环吡咯并三唑酮化合物及其使用方法
CN109912574A (zh) * 2019-05-06 2019-06-21 合肥工业大学 一种二氢吡唑类化合物及其制备方法和用途
JP7367062B2 (ja) * 2019-05-09 2023-10-23 ▲勁▼方医▲薬▼科技（上海）有限公司 ビス複素環式カルボニル置換ジヒドロピラゾール化合物、その調製方法、及びその医薬的使用
WO2020237047A1 (en) * 2019-05-22 2020-11-26 Agios Pharmaceuticals, Inc. Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
WO2021046515A1 (en) 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
IL291665B2 (en) 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
BR112022010082A2 (pt) 2019-11-26 2022-08-30 Univ Texas Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica
IL298188A (en) 2020-05-20 2023-01-01 Sironax Ltd Circular structures of piperazine
JP7774579B2 (ja) * 2020-05-20 2025-11-21 シロナックス リミテッド． ピペラジン複素環アミド尿素類を含む受容体共役タンパク質１阻害剤
KR20230012582A (ko) * 2020-05-20 2023-01-26 시로낙스 엘티디 아제티딘 환형 우레아
TW202214617A (zh) 2020-06-02 2022-04-16 法商賽諾菲公司 作為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途
CN117500795A (zh) * 2021-03-18 2024-02-02 维泰瑞隆有限公司 受体相互作用蛋白1抑制剂、其制备及用途
IL308348A (en) * 2021-05-20 2024-01-01 Sironax Ltd RIP1 modulators including cyclic ureas aztidine, their preparation and uses
CN117460722A (zh) 2021-08-10 2024-01-26 艾伯维公司 烟酰胺ripk1抑制剂
JP2024544533A (ja) 2021-11-11 2024-12-03 ジェンザイム・コーポレーション Ｒｉｐｋ１阻害剤としてのイソオキサゾリジン及びその使用
CN116496256B (zh) * 2022-01-04 2025-03-28 北京赛特明强医药科技有限公司 羰基桥连杂环类化合物、及其组合物与应用
US11816144B2 (en) * 2022-03-31 2023-11-14 Pinterest, Inc. Hair pattern determination and filtering
CN115326999B (zh) * 2022-10-12 2022-12-27 深圳市海滨制药有限公司 一种奥司他韦环氧中间体及其异构体的检测方法
WO2024233544A1 (en) 2023-05-10 2024-11-14 Genzyme Corporation Isoxazolidines as ripk1 inhibitors and use thereof
CN121079291A (zh) 2023-05-10 2025-12-05 建新公司 作为ripk1抑制剂的异噁唑烷及其使用
CN121487930A (zh) 2023-05-10 2026-02-06 建新公司 作为ripk1抑制剂的异噁唑烷及其用途
WO2025045281A2 (zh) 2023-08-31 2025-03-06 杭州百诚医药科技股份有限公司 苯并氮杂䓬酮类化合物及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH062742B2 (ja) 1987-06-17 1994-01-12 三井東圧化学株式会社 新規２‐ピラゾリン類及びそれを有効成分とする脳血管障害治療剤
HU202106B (en) * 1987-06-17 1991-02-28 Mitsui Toatsu Chemicals Process for producing pharmaceutical compositions containing pyrazolin derivatives
US4895947A (en) 1987-12-17 1990-01-23 Mitsui Toatsu Chemicals, Inc. Process for producing 1-acyl-2-pyrazoline derivative
CL2004000366A1 (es) 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
EP1633349A1 (en) 2003-05-02 2006-03-15 Elan Pharmaceuticals, Inc. 4-bromo-5- (2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-(aminocarbonyl) eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
AR053662A1 (es) 2005-01-21 2007-05-16 Astex Therapeutics Ltd Compuestos de pirazol inhibidores de la actividad quinasa cdk y gsk
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP2012513481A (ja) 2008-12-23 2012-06-14 プレジデント アンド フェロウズ オブ ハーバード カレッジ ネクロトーシスの小分子阻害剤
PE20131343A1 (es) 2010-09-21 2013-11-18 Eisai Randd Man Co Ltd Derivados de acido benzoico
US9643977B2 (en) * 2011-03-11 2017-05-09 President And Fellows Of Harvard College Necroptosis inhibitors and methods of use therefor
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
TWI637951B (zh) * 2013-02-15 2018-10-11 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類
EP3224245B1 (en) * 2014-12-24 2018-09-12 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
TWI730959B (zh) 2015-05-19 2021-06-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
WO2017096301A1 (en) 2015-12-04 2017-06-08 Denali Therapeutics Inc. Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (ripk 1)
TW201831464A (zh) 2016-11-18 2018-09-01 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
US20200062735A1 (en) 2017-02-27 2020-02-27 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors

Also Published As

Publication number Publication date
AU2019201480B2 (en) 2020-06-11
SMT202100101T1 (it) 2021-03-15
PH12017502090A1 (en) 2018-05-07
US20180134665A1 (en) 2018-05-17
PE20180508A1 (es) 2018-03-09
LT3298002T (lt) 2021-01-11
CN107624111A (zh) 2018-01-23
PT3298002T (pt) 2020-12-28
ZA201707176B (en) 2019-05-29
HUE053564T2 (hu) 2021-07-28
US20230120185A1 (en) 2023-04-20
EA201792535A1 (ru) 2018-10-31
JP6700311B2 (ja) 2020-05-27
CA2986102A1 (en) 2016-11-24
MA42109A (fr) 2018-03-28
CA2986102C (en) 2024-01-02
AU2019201480C1 (en) 2021-11-25
CO2017011754A2 (es) 2018-02-09
ES2848398T3 (es) 2021-08-09
CR20170524A (es) 2018-01-22
HK1245244A1 (en) 2018-08-24
AU2016263156A1 (en) 2017-11-16
CN107624111B (zh) 2020-11-03
CL2017002908A1 (es) 2018-04-20
MY192059A (en) 2022-07-25
DOP2017000267A (es) 2018-01-31
MX2017014809A (es) 2018-02-09
CN112370452A (zh) 2021-02-19
TW201718508A (zh) 2017-06-01
US10590085B2 (en) 2020-03-17
PL3298002T3 (pl) 2021-06-14
JP2018515555A (ja) 2018-06-14
IL255246A0 (en) 2017-12-31
WO2016185423A1 (en) 2016-11-24
EP3298002A1 (en) 2018-03-28
JP2021138731A (ja) 2021-09-16
MA42109B1 (fr) 2021-03-31
TWI730959B (zh) 2021-06-21
US20200165205A1 (en) 2020-05-28
AU2019201480A1 (en) 2019-03-28
EA036452B1 (ru) 2020-11-12
EP3298002B1 (en) 2020-12-16
JP2020143079A (ja) 2020-09-10
HRP20210300T1 (hr) 2021-04-02
US11485710B2 (en) 2022-11-01
SG11201708707UA (en) 2017-12-28
JP7204821B2 (ja) 2023-01-16
NZ736665A (en) 2024-10-25
US10899716B2 (en) 2021-01-26
UY36680A (es) 2016-12-30
RS61568B1 (sr) 2021-04-29
AU2016263156B2 (en) 2018-12-06
US20210253532A1 (en) 2021-08-19
DK3298002T3 (da) 2021-02-15
JP6893271B2 (ja) 2021-06-23
CY1124187T1 (el) 2022-05-27
BR112017024941A2 (pt) 2018-07-31
MX383935B (es) 2025-03-14
SI3298002T1 (sl) 2021-04-30

Similar Documents

Publication Publication Date Title
JP7204821B2 (ja) キナーゼ阻害剤である複素環式アミド
US10961258B2 (en) Heterocyclic amides as kinase inhibitors
EP4139286B1 (en) Substituted aminothiazoles as dgkzeta inhibitors for immune activation
CA2934137C (en) Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments
US20170266199A1 (en) Heterocyclic amides as rip1 kinase inhibitors as medicaments
WO2019224773A1 (en) Heterocyclic amides as rip1 kinase inhibitors
EP3732176A1 (en) Heterocyclic amides as kinase inhibitors
HK1245244B (en) Heterocyclic amides as kinase inhibitors
BR112017024941B1 (pt) Compostos amidas heterocíclicas, composição farmacêutica que os compreende, bem como uso dos compostos no tratamento de doenças mediadas por proteína quinase rip1

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171115

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210517

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230711

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240329